Lipoprotein(A) Concentrations In Rheumatoid Arthritis On Biologic Therapy: Results From The Cardiovascular In Rheumatology [Carma] Study Project
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
García Gómez, Carmen; Martín Martínez, Maria A.; Castañeda, Santos; Sanchez Alonso, Fernando; Uriarte Ecenarro, Miren; González Juanatey, Carlos; Romera Baures, Montserrat; Santos Rey, José; Pinto Tasende, José Antonio; Quesada Masachs, Estefanía; Tornero Molina, Jesús; Martínez González, Olga; Cobo Ibáñez, Tatiana; Chamizo Carmona, Eugenio; Manrique Arija, Sara; Fábregas Canales, Dolores; Díaz González, Federico; Llorca Díaz, Francisco Javier; González-Gay Mantecón, Miguel ÁngelFecha
2017Derechos
© 2017, Elsevier. Licensed under the Creative Commons Reconocimiento-NoComercial-SinObraDerivada
Publicado en
Journal of Clinical Lipidology (2017), Volume 11, Issue 3, May-June 2017, Pages 749-756.e3
Editorial
Elsevier
Enlace a la publicación
Palabras clave
Rheumatoid arthritis
Cardiovascular disease
Lipoprotein(a)
Biologics
Tocilizumab
Resumen/Abstract
Background
Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved.
Objective
The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics.
Methods
Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors.
Results
Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (?: ?0.303, 95% confidence interval: ?0.558 to ?0.047; P = .02).
Conclusions
RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.
Colecciones a las que pertenece
- D22 Artículos [869]